DETERMINATION OF NADIR GROWTH HORMONE CONCENTRATION CUTOFF IN PATIENTS WITH ACROMEGALY

被引：11

作者：

Bancos, Irina ^{[1
]}

Algeciras-Schimnich, Alicia ^{[2
]}

Woodmansee, Whitney W. ^{[3
]}

Cullinane, Alison K. ^{[3
]}

Donato, Leslie J. ^{[2
]}

Nippoldt, Todd B. ^{[1
]}

Natt, Neena ^{[1
]}

Erickson, Dana ^{[1
]}

机构：

[1] Mayo Clin, Div Endocrinol Metab & Nutr, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA

[3] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA

来源：

ENDOCRINE PRACTICE | 2013年 / 19卷 / 06期

基金：

美国国家卫生研究院;

关键词：

GLUCOSE-TOLERANCE TEST; ORAL GLUCOSE; FACTOR-I; POSTOPERATIVE-PATIENTS; CONSENSUS STATEMENT; GH SECRETION; IGF-1; LEVELS; REMISSION; CRITERIA; CURE;

D O I：

10.4158/EP12435.OR

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: The purpose of this study was to define an appropriate nadir growth hormone (nGH) cutoff for patients with acromegaly in remission using the Access Ultrasensitive human growth hormone (hGH) assay (Beckman Coulter, Brea, CA). Methods: This cross-sectional study included 55 acromegalic subjects and 41 healthy adult volunteers. All subjects underwent oral glucose tolerance testing (OGTT) for growth hormones (GHs). An optimal cutoff for nGH for patients with active disease versus those in remission was determined using receiver-operating curve analysis. Results: The nGH of 0.53 ng/mL revealed a sensitivity of 97% (95% confidence interval [CI], 83-100%) and a specificity of 100% (95% CI, 82-100%). All 22 patients with acromegaly in remission suppressed GH to <1 ng/mL, 20/22 (91%) suppressed to <0.4 ng/mL, and 19/22 (86%) of subjects suppressed to <0.3 ng/mL (the maximum nGH measured in our healthy volunteer group). Conclusion: When using the Access Ultrasensitive hGH assay for OGTT, a cutoff of 0.53 ng/mL was found to most accurately differentiate patients with acromegaly in remission from those with active disease.

引用

页码：937 / 945

页数：9

共 26 条

[1] Comparison of oral glucose tolerance test (OGTT) 100 g with OGTT 75 g for evaluation of acromegalic patients and the impact of gender on test reproducibility [J].

Arafat, A. M. ;

Mueller, L. ;

Moehlig, M. ;

Mayr, B. ;

Kremenevskaya, N. ;

Pfeiffer, A. F. H. ;

Buchfelder, M. ;

Schoefl, C. .

CLINICAL ENDOCRINOLOGY, 2011, 75 (05) :685-691

[2] Growth hormone response during oral glucose tolerance test:: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index [J].

Arafat, Ayman M. ;

Moehlig, Matthias ;

Weickert, Martin O. ;

Perschel, Frank H. ;

Purschwitz, Johannes ;

Spranger, Joachim ;

Strasburger, Christian J. ;

Schoefl, Christof ;

Pfeiffer, Andreas F. H. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (04) :1254-1262

[3] Diagnostic challenges in acromegaly: a case-based review [J].

Bonert, Vivien .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 :S23-S30

[4] Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: what to follow, GH or IGF-1 values? [J].

Brzana, Jessica A. ;

Yedinak, Chris G. ;

Delashaw, Johnny B. ;

Gultelkin, Hume S. ;

Cook, David ;

Fleseriu, Maria .

PITUITARY, 2012, 15 (04) :562-570

[5] The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly [J].

Carmichael, John D. ;

Bonert, Vivien S. ;

Mirocha, James M. ;

Melmed, Shlomo .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02) :523-527

[6] Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: Should we achieve strict normal GH levels for a biochemical cure? [J].

Costa, ACF ;

Rossi, A ;

Martinelli, CE ;

Machado, HR ;

Moreira, AC .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (07) :3142-3147

[7] Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: A retrospective evaluation of 50 patients [J].

De Marinis, L ;

Mancini, A ;

Bianchi, A ;

Gentilella, R ;

Valle, D ;

Giampietro, A ;

Zuppi, P ;

Anile, C ;

Maira, G ;

Giustina, A .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (05) :616-621

[8] Acromegaly with apparently normal GH secretion: Implications for diagnosis and follow-up [J].

Dimaraki, EV ;

Jaffe, CA ;

DeMott-Friberg, R ;

Chandler, WF ;

Barkan, AL .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3537-3542

[9] Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) [J].

Elmlinger, MW ;

Kühnel, W ;

Weber, MM ;

Ranke, MB .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (06) :654-664

[10] Postoperative evaluation of patients with acromegaly: Clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels [J].

Feelders, RA ;

Bidlingmaier, M ;

Strasburger, CJ ;

Janssen, JAMJL ;

Uitterlinden, P ;

Hofland, LJ ;

Lamberts, SWJ ;

van der Lely, AJ ;

de Herder, WW .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (12) :6480-6489

← 1 2 3 →